Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

Summary

The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for patients with advanced pancreatic cancer.

Timeline

Start

2020-10-16

Primary completion

2022-09-30

Completion

2022-09-30

Publications

• Easty D, McDermott R, Murphy AG, Grogan L, Morris PG, Breathnach OS, Egan K, Toomey S, Horgan A, Power D, Osman N, Parker I, Donachie V, Shevlin A, Barrett A, Nolan M, Marron J, Farr CJ, Hennessy BT. Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer. BMC Cancer. 2026 Jan 15;26(1):255. doi: 10.1186/s12885-025-14512-2.

Drugs

Indications